European Hematology Association Congress | Conference

Englumafusp alfa/Glofitamab Combo Shows Early Responses in R/R Aggressive non-Hodgkin Lymphoma

June 14th 2024

Englumafusp alfa plus glofitamab showed activity and tolerability in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Anemia Does Not Diminish Benefit With Ruxolitinib Treatment in Myelofibrosis

June 14th 2024

Patients with new or worsening anemia from their myelofibrosis did not experience lessened clinical benefit of ruxolitinib treatment.

CD7-Directed CAR T-Cell Therapy WU-CART-007 Is Safe in R/R T-ALL/LBL

June 14th 2024

The CD7-targeted CAR T-cell therapy WU-CART-007 had a manageable safety profile and elicited preliminary efficacy signals in relapsed/refractory T-ALL/LBL.

Frontline Blinatumomab Demonstrates “Impressive” Activity in Down Syndrome B-ALL

June 14th 2024

Blinatumomab consolidation improved MRD clearance over chemotherapy in DS B-ALL patients, according to ALLTogether1 DS study results.

Disease Duration, Elevated WBC Count, and VAF Predict Disease Progression in Polycythemia Vera

June 14th 2024

Time from diagnosis, elevated WBC count, and VAF were all significantly associated with an increased risk of disease progression of polycythemia vera.

Dr Kamdar on Results From a Subgroup Analysis of Liso-Cel in MCL

June 14th 2024

Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.

Dr Aldoss on Responses With WU-CART-007 After Enhanced Lymphodepletion in R/R T-ALL/LBL

June 14th 2024

Ibrahim Aldoss, MD, discusses the impact of enhanced lymphodepletion on responses with WU-CART-007 in relapsed/refractory T-ALL/LBL.

HOVON-146 Study Shows Blinatumomab Boosts B-ALL Outcomes

June 14th 2024

HOVON-146 showed integrating blinatumomab into pre-phase and consolidation therapy improved outcomes in newly diagnosed B-ALL.

Observational Study Finds Progression Common in Lower-Risk Myelofibrosis

June 14th 2024

Over a 4-year period, most patients with lower-risk myelofibrosis experienced disease progression, according to the prospective MOST study.

Liso-Cel Associated With Improved Benefit in Earlier Lines of Therapy in R/R Mantle Cell Lymphoma

June 14th 2024

Clinically meaningful activity was found across all subgroups in a posthoc subgroup analysis of patients with MCL treated with liso-cel.

Zanubrutinib Plus Venetoclax Generates 100% ORR in Treatment-Naive Del17p/TP53+ CLL/SLL

June 14th 2024

Zanubrutinib/venetoclax elicited a 100% overall response rate in untreated chronic lymphocytic leukemia harboring 17p deletions or TP53 mutations.

Ide-Cel Generates Favorable PFS Outcomes in R/R Multiple Myeloma With Lower Tumor Burden

June 14th 2024

Ide-cel induced improved PFS outcomes in patients with relapsed/refractory multiple myeloma with characteristics including lower tumor burden.

Oral ATO/ATRA/Ascorbic Acid Regimen Delivers Durable Responses in APL

August 15th 2023

Harry Gill, MD, discusses the importance of offering patients with APL an entirely oral treatment regimen, key efficacy findings from this trial, and the tolerability of this regimen.

Polatuzumab Vedotin Substitution in R-mini-CHOP Does Not Worsen High-Grade Toxicities in DLBCL

June 13th 2023

Using polatuzumab vedotin instead of vincristine in a reduced-dose regimen of rituximab, cyclophosphamide, doxorubicin, and prednisone was not found to increase grade 3/4 hematologic toxicities, infection risk, or neuropathy in elderly patients with untreated diffuse large B-cell lymphoma.

MASP-3 Inhibitor Demonstrates Clinical Efficacy in Paroxysmal Nocturnal Hemoglobinuria

June 11th 2023

OMS906, a MASP-3 inhibitor, normalized hemoglobin, lactate dehydrogenase, and reticulocytes levels in patients with paroxysmal nocturnal hemoglobinuria.

Phase 3 CLL12 Data Support Watch-and-Wait Approach in Early-Stage CLL

June 11th 2023

Ibrutinib did not prolong survival vs placebo and is linked with increased susceptibility to bleeding in patients with asymptomatic early-stage chronic lymphocytic leukemia, suggesting that a watch-and-wait approach should continue as the standard for this population.

Gilteritinib Shows RFS Benefit as Maintenance, Posttransplant Therapy in MRD+ FLT3-Mutant AML

June 11th 2023

Gilteritinib led to a 48% reduction in disease recurrence for patients with FLT3-ITD–mutant acute myeloid leukemia and detectable minimal residual disease pre and post hematopoietic stem cell transplant compared with placebo, highlighting a role for treatment in this subgroup of patients.

Venetoclax Plus Rituximab Provides Long-Term Survival Benefit in Relapsed/Refractory CLL

June 11th 2023

Treatment with fixed-duration venetoclax plus rituximab continued to show superior survival benefit vs bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia, according to 7-year follow up data from the phase 3 MURANO trial.

BMS-986158 Plus Rituximab Reduces Spleen Volume, Shows Tolerability in Myelofibrosis

June 11th 2023

The BET inhibitor BMS-986158 combined with ruxolitinib led to robust spleen volume reduction with acceptable tolerability in patients with myelofibrosis. When the BET inhibitor was combined with fedratinib, the safety profile was also determined to be manageable.

Cilta-Cel Demonstrates Long-Term PFS, Safety in R/R Multiple Myeloma

June 11th 2023

Administration of a single infusion of ciltacabtagene autoleucel prolonged progression-free survival, generated sustained responses, and continued to demonstrate a manageable safety profile in patients with relapsed/refractory multiple myeloma who were heavily pretreated, according to final results from the phase 1b/2 CARTITUDE-1 study.